Suppr超能文献

正常受试者以及接受血液透析或腹膜透析的肾衰竭患者静脉注射头孢曲松后的药代动力学情况。

Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis.

作者信息

Ti T Y, Fortin L, Kreeft J H, East D S, Ogilvie R I, Somerville P J

出版信息

Antimicrob Agents Chemother. 1984 Jan;25(1):83-7. doi: 10.1128/AAC.25.1.83.

Abstract

The kinetic disposition of a single intravenous dose of ceftriaxone (250 to 665 mg) was studied in six normal subjects and nine patients with renal insufficiency and normal hepatic function. In normal subjects, ceftriaxone was eliminated with a t1/2 beta of 5.2 h (range, 4.1 to 5.8). The total body clearance (Qb) was 13.5 ml/kg per h (range, 8.4 to 23.3), and renal clearance was 8.3 ml/kg per h (range, 5.8 to 13.3). In patients with severe renal insufficiency requiring peritoneal or hemodialysis, the mean t1/2 beta was prolonged to 13.4 h (range, 7.7 to 15.8) and the mean Qb was reduced to 6.9 ml/kg per h (range, 3.4 to 12.8). The apparent volumes of distribution (Vc and Vss) were not different from those determined in normal subjects. Peritoneal dialysis did not remove ceftriaxone. The dialysate of three patients on continuous peritoneal dialysis did not contain any measureable ceftriaxone, and the kinetic disposition in these patients was similar to the hemodialysis patients between their dialysis treatment. During a 4-h hemodialysis session, the total body clearance of ceftriaxone was reduced, perhaps secondary to a decrease in hepatic blood flow induced by the hemodialysis procedure. After a 12- or 24-h dose regimen, predicted trough concentrations of ceftriaxone in plasma at steady state derived from kinetic data generated from the study and assuming linear pharmacokinetic behavior were well above the minimum inhibitory concentrations of most sensitive bacteria, suggesting the feasibility of a once-a-day dosage regimen especially for patients with severe renal insufficiency.

摘要

在6名正常受试者和9名肾功能不全但肝功能正常的患者中,研究了单次静脉注射头孢曲松(250至665毫克)后的动力学处置情况。在正常受试者中,头孢曲松的消除半衰期(t1/2β)为5.2小时(范围为4.1至5.8小时)。总体清除率(Qb)为每小时13.5毫升/千克(范围为8.4至23.3),肾清除率为每小时8.3毫升/千克(范围为5.8至13.3)。在需要腹膜透析或血液透析的严重肾功能不全患者中,平均t1/2β延长至13.4小时(范围为7.7至15.8小时),平均Qb降至每小时6.9毫升/千克(范围为3.4至12.8)。表观分布容积(Vc和Vss)与正常受试者中测定的值无差异。腹膜透析不能清除头孢曲松。三名接受持续腹膜透析患者的透析液中未检测到任何可测量的头孢曲松,这些患者的动力学处置情况与血液透析患者在透析治疗期间的情况相似。在4小时的血液透析过程中,头孢曲松的总体清除率降低,这可能是由于血液透析过程导致肝血流量减少所致。在12或24小时给药方案后,根据该研究生成的动力学数据并假设线性药代动力学行为预测的稳态时血浆中头孢曲松的谷浓度远高于大多数敏感细菌的最低抑菌浓度,这表明每日一次给药方案对于严重肾功能不全患者尤其可行。

相似文献

5
Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis.
Clin Pharmacol Ther. 1985 Sep;38(3):285-9. doi: 10.1038/clpt.1985.172.

引用本文的文献

3
Daily variations in ceftriaxone pharmacokinetics in rats.大鼠体内头孢曲松药代动力学的每日变化
Antimicrob Agents Chemother. 2003 Feb;47(2):809-12. doi: 10.1128/AAC.47.2.809-812.2003.
8
Clinical pharmacokinetics of the third generation cephalosporins.第三代头孢菌素的临床药代动力学
Clin Pharmacokinet. 1985 Mar-Apr;10(2):101-43. doi: 10.2165/00003088-198510020-00001.

本文引用的文献

7
Efficacy of ceftriaxone in serious bacterial infections.头孢曲松在严重细菌感染中的疗效。
Antimicrob Agents Chemother. 1982 Mar;21(3):402-6. doi: 10.1128/AAC.21.3.402.
9
Pharmacokinetics of ceftriaxone in humans.头孢曲松在人体内的药代动力学。
Antimicrob Agents Chemother. 1981 Nov;20(5):634-41. doi: 10.1128/AAC.20.5.634.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验